🎗️ Balversa (erdafitinib) was recommended for the treatment of adult patients with urothelial carcinoma.
👃 Eurneffy (epinephrine) was recommended as the first emergency treatment for allergic reactions in nasal spray form.
💉 mResvia (RSV mRNA vaccine) received a positive opinion for preventing respiratory syncytial virus in adults.
💊 Ordspono (odronextamab) was recommended for the treatment of follicular and diffuse large B-cell lymphoma.
🩸 Piasky (crovalimab) received a positive opinion for paroxysmal nocturnal haemoglobinuria.
🧠 Tauvid (flortaucipir) was recommended for PET imaging of the brain in patients with cognitive impairment.
🫀 Winrevair (sotatercept) received a marketing authorisation for treating pulmonary arterial hypertension.
🍀 Steqeyma (ustekinumab) was recommended for the treatment of Crohn’s disease, plaque psoriasis, and psoriatic arthritis.
💊 Enzalutamide Viatris (enzalutamide) and Nilotinib Accord (nilotinib) received positive opinions as generic medicines.
🔍 More details in the news announcement on the website.
Introduction:
EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting. The recommendations include treatments for various conditions such as urothelial carcinoma, allergic reactions, respiratory syncytial virus, blood cancer, paroxysmal nocturnal haemoglobinuria, Alzheimer’s disease, pulmonary arterial hypertension, Crohn’s disease, plaque psoriasis, psoriatic arthritis, prostate cancer, and chronic myelogenous leukaemia.
- Balversa (erdafitinib) was recommended for the treatment of adult patients with unresectable or metastatic urothelial carcinoma.
- Eurneffy (epinephrine) received a positive opinion as the first emergency treatment against allergic reactions that is administered as a nasal spray.
- mResvia (Respiratory Syncytial Virus (RSV) mRNA vaccine) was recommended for prevention in adults 60 years of age and older of lower respiratory tract disease and acute respiratory disease caused by respiratory syncytial virus.
- Ordspono* (odronextamab) received a conditional marketing authorization for the treatment of follicular lymphoma and diffuse large B-cell lymphoma.
- Piasky (crovalimab) was recommended for the treatment of paroxysmal nocturnal haemoglobinuria.
- Tauvid (flortaucipir (18F)) received a positive opinion for PET imaging of the brain in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease.
- Winrevair* (sotatercept) was recommended for the treatment of adult patients with pulmonary arterial hypertension.
- Steqeyma (ustekinumab) was recommended as a biosimilar medicine for the treatment of adult patients with Crohn’s disease, plaque psoriasis, paediatric plaque psoriasis, and psoriatic arthritis.
- Enzalutamide Viatris (enzalutamide) received a positive opinion for the treatment of prostate cancer.
- Nilotinib Accord (nilotinib) received a positive opinion for the treatment of Philadelphia chromosome positive chronic myelogenous leukaemia.
Conclusion:
The European Medicines Agency’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting. These recommendations offer new treatment options for patients with various conditions, including urothelial carcinoma, allergic reactions, respiratory syncytial virus, blood cancer, paroxysmal nocturnal haemoglobinuria, Alzheimer’s disease, pulmonary arterial hypertension, Crohn’s disease, plaque psoriasis, psoriatic arthritis, prostate cancer, and chronic myelogenous leukaemia. This is a significant step forward in providing effective and safe therapies for patients in need.
